Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enanta Pharmaceuticals, Inc. (ENTA : NSDQ)

• Company Description    Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. Number of Employees: 120

• Price / Volume Information    Yesterday's Closing Price: $13.95 Daily Weekly Monthly 20 Day Moving Average: 202,214 shares Shares Outstanding: 29.08 (millions) Market Capitalization: $405.64 (millions) Beta: 1.01 52 Week High: $17.15 52 Week Low: $5.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.49% -0.61% 12 Week -3.19% -10.51% Year To Date -11.54% -19.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4 KINGSBURY AVENUE - WATERTOWN,MA 02472 USA ph: 617-607-0800 fax: 617-607-0530 ir@enanta.com http://www.enanta.com

• General Corporate Information    Officers Jay R. Luly - President and Chief Executive Officer and Director Harry R. Trout - Vice President; Finance Bruce L.A. Carter - Director Mark G. Foletta - Director Yujiro S. Hata - Director Peer Information Enanta Pharmaceuticals, Inc. (CORR.) Enanta Pharmaceuticals, Inc. (RSPI) Enanta Pharmaceuticals, Inc. (CGXP) Enanta Pharmaceuticals, Inc. (BGEN) Enanta Pharmaceuticals, Inc. (GTBP) Enanta Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29251M106 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 29.08 Most Recent Split Date: (:1) Beta: 1.01 Market Capitalization: $405.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.48 Price/Cash Flow: - Price / Sales: 5.86 EPS Growth vs. Year Ago Period: 57.55% vs. Previous Quarter: -7.14% Sales Growth vs. Year Ago Period: 14.96% vs. Previous Quarter: -7.82% ROE 03/31/26 - -64.04 12/31/25 - -78.58 09/30/25 - -93.76 ROA 03/31/26 - -20.22 12/31/25 - -23.18 09/30/25 - -26.13 Current Ratio 03/31/26 - 3.84 12/31/25 - 4.44 09/30/25 - 4.21 Quick Ratio 03/31/26 - 3.84 12/31/25 - 4.44 09/30/25 - 4.21 Operating Margin 03/31/26 - -89.56 12/31/25 - -106.80 09/30/25 - -125.36 Net Margin 03/31/26 - -89.56 12/31/25 - -106.80 09/30/25 - -125.36 Pre-Tax Margin 03/31/26 - -89.42 12/31/25 - -108.62 09/30/25 - -127.90 Book Value 03/31/26 - 4.01 12/31/25 - 4.36 09/30/25 - 3.03 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 1.11 12/31/25 - 1.02 09/30/25 - 1.99

Powered by Zacks Investment Research ©